Altogether, we observed that several alterations in clinically actionable cancer genes are private to or enriched for in PR− breast cancers, such as TP53 R342X, P728S, I195T, and H179R, GATA3, CDH1, HER2, CDH1, and BRAF V600E. This evidence concerns the gene CDH1 and breast cancer.